Last reviewed · How we verify
IAH0968
At a glance
| Generic name | IAH0968 |
|---|---|
| Sponsor | SUNHO（China）BioPharmaceutical CO., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer (PHASE2, PHASE3)
- To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer (PHASE2, PHASE3)
- IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors (PHASE1, PHASE2)
- Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IAH0968 CI brief — competitive landscape report
- IAH0968 updates RSS · CI watch RSS
- SUNHO（China）BioPharmaceutical CO., Ltd. portfolio CI